Source: Eur Respir J 2011; 37: 36-41
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Singanayagam A., Chalmers J.D., Akram A.R., Hill A.T.. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 37: 36-41

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients Source: Eur Respir J 2012; 39: 855-861 Year: 2012 Risk of pneumonia in chronic obstructive pulmonary disease patients treated with inhaled corticosteroids. Results from the OUTPUL study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010 Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007